"Is Empagliflozin a Diabetes 'Game Changer'?"
"When a new version of inhaled insulin was approved less than 2 years ago, it had the potential to become a major component of diabetes treatment. However, given the recent announcement that pharmaceutical giant Sanofi will stop distributing Afrezza® after a year of poor sales, it is unlikely that the product developed by Mannkind will change the diabetes landscape."
Click here to read the full article
Source- http://www.medscape.com/viewarticle/859551
